T1 Organism 335 348 2000 and 2011
T2 Biomarker 897 906 erlotinib
T3 Biomarker 669 680 bevacizumab
T5 Biomarker 911 921 pemetrexed
T6 Biomarker 1182 1190 spending
T7 Intervention 1396 1416 advanced-stage NSCLC
T8 Biomarker 626 636 pemetrexed
T9 Organism 862 870 Patients
T10 Organism 229 237 patients
T11 Intervention 1087 1101 antineoplastic
T12 Biomarker 161 169 spending
T13 Organism 1069 1077 patients
T15 Intervention 1594 1600  NSCLC
T16 Protein 1276 1282 37,931
T17 Intervention 262 282 advanced-stage NSCLC
T18 Biomarker 706 716 paclitaxel
T19 Biomarker 1246 1254 spending
T20 Protein 1207 1213 29,376
T21 Biomarker 726 737 gemcitabine
T22 Intervention 305 319 antineoplastic
T23 Biomarker 476 484 spending
T24 Organism 403 411 patients
T25 Biomarker 646 655 erlotinib
T26 Biomarker 884 895 bevacizumab
T27 Intervention 1580 1600 advanced-stage NSCLC
T28 Biomarker 1481 1489 spending
T30 Condition 36 63 nonâ€“small-cell lung cancer 
